When was Acclinate founded?

Acclinate was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Acclinate located?

Acclinate is headquartered in Birmingham, United States.

Who is the current CEO of Acclinate?

Delmonize Del Smith of Acclinate.

How many employees does Acclinate have?

As of Oct 31, 2026, the latest employee count at Acclinate is 47.

Is Acclinate a funded company?

Acclinate is a funded company, having raised a total of $15.5M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 25, 2020.

When was the latest funding round of Acclinate?

Acclinate's latest funding was a $***** Series A round on Feb 11, 2026, with participation from 0 investor.

Where does Acclinate rank among its competitors?

Acclinate ranks 5th amongst 373 active competitors, of which 41 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Biofortuna, which secured $303K in Feb, 2026.

Who are the top competitors of Acclinate?

Acclinate's top competitors include Novartis, Catalent and Surrozen. Among them, Biofortuna secured the most recent funding round in February, 2026.

Acclinate - 2026 Company Profile, Team, Funding & Competitors

Company Details

Website: www.acclinate.com/
Social
Email ID: *****@acclinate.com
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Birmingham, United States

Stage

Series A

Total Funding

$15.5M in 6 rounds

Latest Funding Round

Series A, Feb 11, 2026, $*****

Investors

Alabama Launchpad & 8 more

Ranked

5^th among 373 active competitors

Employee Count

47 as on Oct 31, 2026

Similar Companies

Novartis & 426 more

View Acclinate's full profile

Acclinate is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Acclinate, Inc CIN: 850491564 , United States, Active	Dec 31, 2018	-	43 (As on Dec 31, 2024)	-

Acclinate has raised a total funding of $15.5M over 6 rounds. Its first funding round was on Feb 25, 2020. Acclinate has 9 institutional investors.

Here is the list of recent funding rounds of Acclinate:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 11, 2026	2553693	Series A	5069464	4908108	8513089	7180747
May 03, 2024	8751724	Series A	8815620	3378441	2753192	LabCorp & 1 more
Oct 19, 2022	2466893	Series A	6927773	2465632	6391064	6725586

Access funding benchmarks and valuations. Sign up today!

View details of Acclinate's funding rounds and investors

The founders of Acclinate is Delmonize Del Smith.

Here are the details of Acclinate's key team members:

Delmonize Del Smith: Co-Founder & CEO of Acclinate.
Contact Info: 1 email address

View details of Acclinate's Founder profiles and Board Members

Acclinate's employee count trend

Acclinate has 47 employees as of Oct 26. Here is Acclinate's employee count trend over the years:

Uncover Acclinate's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Acclinate include Novartis, Catalent and Surrozen. Here is the list of Top 10 competitors of Acclinate, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
2nd	Catalent 2007, Somerset (United States), Acquired	Provider of development, manufacturing, and packaging solutions for medicines and supplements	-	Aisling Capital, JPMorgan Chase & 4 others	68/100
3rd	Surrozen 2016, San Francisco (United States), Public	Pioneering targeted regenerative antibodies to repair tissue and restore organ function	$133M	The Column Group, Horizons Ventures & 13 others	59/100
4th	Biofortuna 2008, Birkenhead (United Kingdom), Series A	Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services	$21.6M	Foresight Group, Gov Wales & 12 others	55/100
5th	Acclinate 2020, Birmingham (United States), Series A	Provider of clinical trial services to biopharma sector	$15.5M	LabCorp, Johnson & Johnson Innovation & 7 others	52/100
6th	Curia 1991, Albany (United States), Acquired	Provider of drug research & development, testing, and consulting services	-	HarbourVest Partners, Thecarlylegroup.fr & 6 others	53/100
7th	WuXi Biologics 2008, Shanghai (China), Public	Developer and manufacturer for protein therapeutics	-	Pivotal bioVenture Partners, HongShan & 3 others	52/100
8th	Sunflower Therapeutics 2018, Hingham (United States), Series A	Provider of drug development & research services for multiple therapeutic areas	$5.64M	NIAID, Clear Current Capital & 3 others	52/100
9th	Ventus Therapeutics 2019, Boston (United States), Series C	Develops small‑molecule therapeutics for autoimmune and auto‑inflammatory diseases treatment	$300M	RA Capital Management, Versant Ventures & 10 others	51/100
10th	BioFactura 2004, Frederick (United States), Series B	Biosimilars, biodefense, and biomanufacturing company dedicated to innovation and global biomedical needs	$7.8M	Wilson Sonsini Goodrich & Rosati, UVM Health ... & 2 others	51/100